Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
Lilly(LLY) The Motley Fool·2024-08-04 09:26Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death.Shares of Eli Lilly (LLY -3.36%) notched a 3.5% gain on Thursday, Aug. 1, after the company reported positive clinical trial results for its increasingly successful weight management treatment. It looks like certain patients treated with tirzepatide were significantly less likely to suffer cardiovascular death and other heart failure outcomes c ...